Recovery is Achievable: Biocatalytic approaches to Diversifying Mitragynine Analogs for Opioid Substitution Therapies
康复是可以实现的:生物催化方法使帽柱木碱类似物多样化用于阿片类药物替代疗法
基本信息
- 批准号:10386083
- 负责人:
- 金额:$ 3.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAlkaloidsAmericanAnabolismAnalgesicsAttentionBindingBiochemicalBiochemistryClinical ResearchConstipationCyclizationDehydrationDependenceDevelopmentDisease ManagementEngineeringEnzyme TestsEnzymesExhibitsEyeGTP-Binding ProteinsGenerationsGenomeGoalsHomologous GeneHydroxylationIndole AlkaloidsLibrariesLifeMammalsMedicinal HerbsMedicinal PlantsMental DepressionMethadoneMethodsMethylationMiningMitragynaMolecularMonoterpenesMorphineNatural ProductsOpiate AddictionOpioidOpioid ReceptorOpioid RotationOpioid agonistOpioid replacement therapyOrganismPain managementPathway interactionsPatternPharmaceutical PreparationsPharmacologyPlant alkaloidPlantsProductionPropertyProtein EngineeringReactionRecoveryRelapseReportingResearchRouteSignaling ProteinSoutheastern AsiaStimulantStructureStructure-Activity RelationshipTherapeuticTreesUnited States Food and Drug AdministrationVentilatory Depressionaddictionanalogantagonistbasecatalystchronic pain managementdelta opioid receptordesigndrug discoveryenzyme pathwayexperiencefallsflexibilityfunctional groupimprovedmitragynine pseudoindoxylmu opioid receptorsnon-Nativenovelopioid epidemicopioid overdoseopioid use disorderopioid withdrawaloverdose deathpain reliefpandemic diseasereconstitutionresponsescaffoldside effectsmall moleculestereochemistrystrictosidine
项目摘要
Proposal Summary
Kratom (Mitragyna speciosa) is a medicinal plant that has been used in Southeast Asia for hundreds of years to
self-treat chronic-pain, opioid with-drawl, and depression. Due to these unique pharmacological effects, in the
past decade Kratom has flourished in the U.S. with many users self-treating opioid use disorder and pain
management. This medicinal herb has become a life-raft many use to pull themselves out of the pit of addiction,
rather than continuously falling in the trap of relapsing. Despite the recent attention, this plant remains
controversial in the eyes of the Food and Drug Administration and the Drug Enforcement Administration due to
limited or preliminary clinical research. Although, several studies have been conducted on Kratom’s primary
alkaloid mitragynine, characterizing it a partial antagonist of the μ-opioid receptor activated through the G-protein
signaling cascade. Kratom users report pain relieving properties and a depletion in negative side effects such as
constipation, addiction, and respiratory depression compared to morphine-based opioids. Furthermore, studies
show that some mitragynine analogs such as mitragynine pseudoindoxyl and 7-hydroxymitragynine are even
more potent agonists of the µ-opioid receptor, although a complete structure activity relationship of these
alkaloids has not been established. Thus, unanswered questions remain regarding where and how to manipulate
mitragynine to be the ultimate opioid substitution drug. Our goal is to fully elucidate the biosynthetic pathway of
mitragynine to determine the biocatalytic transformations required to produce the mitragynine scaffold.
Determining the biocatalytic pathway opens the door to manipulate critical catalysts that form mitragynine to
produce analogs that may enhance the pharmacological properties already displayed from this unique alkaloid.
Furthermore, we plan to derivatize mitragynine even further by characterizing and engineering flexible catalysts
from other organisms to produce mitragynine analogs with alternative cyclization, stereochemistry or functional
group patterns. Through this study we will generate a library of mitragynine analogs with the goal of identifying
effective candidates to help treat opioid use disorder. The overreaching hypothesis is that through methods of
protein engineering we can diversify the mitragynine scaffold beyond what is attainable through general synthetic
approaches and prepare novel compounds with enhanced pharmacological properties concerning opioid
response. Ultimately, mitragynine analogs have the potential to fast-track the development of new and safer
treatments for opioid use disorders therefore permanently improving the lives of those affected.
提案摘要
卡痛叶(Mitragyna speciosa)是一种药用植物,在东南亚已有数百年的历史
自我治疗慢性疼痛、阿片类药物戒断和抑郁症。由于这些独特的药理作用,
过去十年,卡痛在美国蓬勃发展,许多用户自行治疗阿片类药物使用障碍和疼痛
管理。这种药草已成为许多人用来摆脱毒瘾深渊的救生筏,
而不是不断陷入旧病复发的陷阱。尽管最近受到关注,这种植物仍然
由于以下原因,食品药品监督管理局和缉毒局认为存在争议
有限或初步的临床研究。尽管如此,已经对卡痛的主要成分进行了多项研究
生物碱帽柱木碱,其特征在于它是通过 G 蛋白激活的 μ-阿片受体的部分拮抗剂
信号级联。卡痛叶使用者表示,卡痛具有缓解疼痛的功效,并减少了负面副作用,例如
与基于吗啡的阿片类药物相比,便秘、成瘾和呼吸抑制。此外,研究
表明一些帽柱木碱类似物,例如帽柱木碱假吲哚酚和7-羟基帽柱木碱,甚至是
µ-阿片受体的更有效激动剂,尽管这些药物的完整结构活性关系
生物碱尚未确定。因此,关于在哪里以及如何操纵的问题仍然悬而未决。
帽柱木碱成为最终的阿片类药物替代药物。我们的目标是充分阐明其生物合成途径
帽柱木碱以确定生产帽柱木碱支架所需的生物催化转化。
确定生物催化途径为操纵形成帽柱木碱的关键催化剂打开了大门
产生的类似物可以增强这种独特生物碱已经表现出的药理学特性。
此外,我们计划通过表征和设计柔性催化剂进一步衍生帽柱木碱
从其他生物体中生产具有替代环化、立体化学或功能性的帽柱木碱类似物
组模式。通过这项研究,我们将建立一个帽柱木碱类似物库,目的是识别
帮助治疗阿片类药物使用障碍的有效候选人。过度的假设是通过以下方法
通过蛋白质工程,我们可以使帽柱木碱支架多样化,超出一般合成所能达到的范围
方法并制备具有增强的阿片类药物药理特性的新型化合物
回复。最终,帽柱木碱类似物有潜力快速开发新的、更安全的药物
因此,阿片类药物使用障碍的治疗可以永久改善受影响者的生活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalia Harris其他文献
Natalia Harris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalia Harris', 18)}}的其他基金
Recovery is Achievable: Biocatalytic approaches to Diversifying Mitragynine Analogs for Opioid Substitution Therapies
康复是可以实现的:生物催化方法使帽柱木碱类似物多样化用于阿片类药物替代疗法
- 批准号:
10557089 - 财政年份:2022
- 资助金额:
$ 3.89万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




